Kura Oncology is trading 5.49% up now at $11.81, moving alongside a broader biotech rally rather than a newly reported company-specific catalyst.
- Biotech’s XBI sector benchmark is up 2.55%, while major U.S. indexes are also higher, supporting risk appetite.
- Kura’s September 16 Morgan Stanley presentation highlighted strong KOMZIFTI sales and pipeline potential; the report did not link those remarks to the September 17 move.